Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Testim Lawsuit Claims Multiple Strokes Caused by Use of Low Testosterone Treatment Drug Notes Wright & Schulte LLC
  • USA - English


News provided by

Wright & Schulte LLC

Apr 21, 2014, 14:30 ET

Share this article

Share toX

Share this article

Share toX

Testim Lawsuit Alleged Multiple Strokes Caused by "Low T" Treatment Drug
Testim Lawsuit Alleged Multiple Strokes Caused by "Low T" Treatment Drug

New York, NY (PRWEB) April 21, 2014 -- Another Testim lawsuit, this one filed in Louisiana (case no.2-14-cv-00839), is claiming low testosterone therapy is behind the multiple strokes suffered by a Jefferson Parish man. Wright & Schulte LLC recently learned of the Testim lawsuit while investigating other Testim and Adrogel Lawsuits (In Re: AndroGel Product Liability Litigation, MDL Docket No. 36).

If your believe you have suffered cardiovascular problems due to testosterone therapy drugs such as Androgel and Testim, Call Wright & Schulte LLC today for a Free Legal Evaluation at 1-800-399-0795 or by visiting www.yourlegalhelp.com

Post this

Wright & Schulte LLC has learned that this Testim lawsuit alleges the use of AndroGel and Testim caused the plaintiff to suffer two strokes. The testosterone treatment complaint, filed April 10, 2014, in U.S. District Court for the Eastern District of Louisiana, seeks damages from AbbVie Inc. and Abbot Laboratories, which manufactures and markets AndroGel, and Auxilium Pharmaceuticals, Inc., the maker of Testim. The complaint accuses the companies of misrepresenting their products as safe, easy to use and free from serious side effects. (case no. 2-14-cv-00839000)

The court documents further state, the plaintiff experienced symptoms to which he attributed to low testosterone based on the defendants’ advertisements. The complaint also contends the plaintiff was prescribed AndroGel and Testim in 2006 when he was 63 years old and continued taking the topical gel products until 2014. The Testim lawsuit further purports that prior to taking the testosterone treatment, he had not had cardiac problems and had he known about the potential risks associated with the therapy, as reported by the FDA Safety Announcement, he would not have had to suffer the serious side effects of the medication. The AndroGel and Testim lawsuit cited a study published in the August 2013 issue of the American Medical Association which found that men who were prescribed testosterone treatment had no evidence of low testosterone, also known as hypogonadism.
[fda.gov/Drugs/DrugSafety/ucm383904.htm, January 31, 2014]

The firm continues to review potential side-effects of low testosterone therapy drugs such as Androgel and Testim in the wake of a recent FDA warning that "Low T" drugs have the potential to cause heart attacks and strokes. Wright & Schulte LLC continues to offer free legal consults to people who believe they have suffered cardiac issues due to the use of Androgel or Testim at yourlegalhelp.com or by calling 1-800-399-0795.

Testosterone Drugs Under Scrutiny by FDA
The U.S. Food & Drug Administration (FDA) approved AndroGel in February 2000, and Testim in October 2002, for use in men who had low testosterone or who could no longer produce testosterone. In May 2009, the agency required the makers of the two prescription drugs to include boxed warnings on the labels of the two topical gel products after receiving reports that children have adverse effects when they are inadvertently exposed to the medication through contact with someone who was taking testosterone replacement therapy. By January 31, 2014, the FDA announced that it was launching an investigation into testosterone replacement therapies based on two studies that found older men or men with pre-existing heart conditions who use these drugs, might be at a higher risk of having strokes, heart attacks and even death.
[fda.gov/Drugs/DrugSafety/DrugSafetyNewsletter/ucm189806.htm, 2009]

Testim Lawsuits
According to court documents, this Testim complaint follows three similar Testim lawsuits filed in the Philadelphia Court of Common Pleas over the "Low T" drug Testim. In one case an Alabama man contends the testosterone gel caused him to suffer neurologic impairment and cognitive deficits and impairment (case no.140301684). In the second Testim complaint (case no 1403025370 a plaintiff from New Jersey alleged that he had a heart attack as a result of using Testim. In the third complaint, filed March 21, a Pennsylvania resident alleged that he had to have heart bypass surgery due to using Testim and AndroGel. (case no. 140303508)

Also in March, plaintiffs in federal testosterone replacement therapy lawsuits asked the U.S. Judicial Panel on Multidistrict Litigation in a petition to consolidate all federally filed AndroGel lawsuits in the Northern District of Illinois. The plaintiffs alleged in their complaints that taking AndroGel caused them to have strokes, heart attacks and other health problems. [In Re: AndroGel Product Liability Litigation, MDL Docket No. 36].

Men who used AndroGel, Testim or a similar drug may be eligible to file their own low testosterone therapy lawsuit if they experienced serious and life-threatening cardiovascular events during treatment. To learn more, or to arrange for a free legal consultation with an attorney at Wright & Schulte LLC, please visit yourlegalhelp.com.

About Wright & Schulte LLC
Wright & Schulte LLC, an experienced personal injury firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright & Schulte LLC stand up for the rights of people who have been injured or wronged and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’re looking for a law firm that will guarantee the aggressive and personal representation you deserve, please do not hesitate to contact Wright & Schulte LLC today. Free Lipitor lawsuit case evaluations are available through yourlegalhelp.com or by calling 1-800-399-0795.

Contact:
Wright & Schulte LLC
1-800-399-0795
http://www.yourlegalhelp.com
Like Us On Facebook Follow Us On Twitter

Richard Schulte, Wright & Schulte LLC, http://www.yourlegalhelp.com, +1 1-800-399-0795, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.